RemeGen Co., Ltd. (SHA:688331)
China · Delayed Price · Currency is CNY 99.68
-0.52 (-0.52%)
At close: Feb 6, 2026
RemeGen Revenue
RemeGen had revenue of 621.88M CNY in the quarter ending September 30, 2025, with 33.13% growth. This brings the company's revenue in the last twelve months to 2.23B, up 46.34% year-over-year. In the year 2024, RemeGen had annual revenue of 1.72B with 58.54% growth.
Revenue (ttm)
2.23B
Revenue Growth
+46.34%
P/S Ratio
22.21
Revenue / Employee
742.85K
Employees
3,070
Market Cap
49.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.72B | 633.91M | 58.54% |
| Dec 31, 2023 | 1.08B | 310.84M | 40.26% |
| Dec 31, 2022 | 772.11M | -651.79M | -45.78% |
| Dec 31, 2021 | 1.42B | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharmaron Beijing | 13.54B |
| Chongqing Zhifei Biological Products | 10.91B |
| Shanghai RAAS Blood Products | 7.95B |
| Beijing Tiantan Biological Products | 6.42B |
| Asymchem Laboratories (Tianjin) | 6.29B |
| Shanghai Allist Pharmaceuticals | 4.76B |
| Haisco Pharmaceutical Group | 4.27B |
| Xiamen Amoytop Biotech | 3.34B |